Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DS5F | ISIN: FR0013254851 | Ticker-Symbol: 8JD
Frankfurt
28.03.24
08:32 Uhr
3,530 Euro
+0,070
+2,02 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VALBIOTIS SA Chart 1 Jahr
5-Tage-Chart
VALBIOTIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,4203,91028.03.

Aktuelle News zur VALBIOTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.01.VALBIOTIS SA: Valbiotis sets out its commercial and clinical roadmap for 20241.702DJ Valbiotis sets out its commercial and clinical roadmap for 2024 VALBIOTIS SA Valbiotis sets out its commercial and clinical roadmap for 2024 16-Jan-2024 / 17:40 CET/CEST Dissemination...
► Artikel lesen
22.12.23VALBIOTIS SA: Valbiotis announces the success of its €15 M capital increase355VALBIOTIS SA Valbiotis announces the success of its €15 M capital increase 22-Dec-2023 / 07:35 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is...
► Artikel lesen
11.12.23VALBIOTIS SA: Valbiotis announces the launch of a capital increase582VALBIOTIS SA Valbiotis announces the launch of a capital increase 11-Dec-2023 / 21:03 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible...
► Artikel lesen
07.11.23VALBIOTIS SA: Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes509VALBIOTIS SA Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes 07-Nov-2023 / 17:40 CET/CEST Dissemination...
► Artikel lesen
02.10.23VALBIOTIS SA: The Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes330VALBIOTIS SA VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for...
► Artikel lesen
28.09.23VALBIOTIS SA: Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap602VALBIOTIS SA Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap 28-Sep-2023 / 17:40 CET/CEST Dissemination of a French Regulatory...
► Artikel lesen
11.09.23VALBIOTIS SA: Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM•63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance484The REVERSE-IT study has met its primary endpoint: TOTUM•63 reduced fasting blood glucose at 6 months versus placebo, on both a 3-intake/day and a 2-intake/day regimen, the optimal regimen for marketing...
► Artikel lesen
12.07.23Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances818DJ Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances VALBIOTIS SA Valbiotis announces its roadmap and strategic...
► Artikel lesen
03.07.23Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member545DJ Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member VALBIOTIS SA Valbiotis announces the appointment of Charlotte JEZEQUEL...
► Artikel lesen
23.05.23Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes547Die Studie erreichte ihr Ziel beim primären Endpunkt, der Senkung des Nüchternblutzuckers Risikofaktor für Typ-2-Diabetes, bei einer Tagesdosis von 5 g und drei Verabreichungen pro Tag mit hoher...
► Artikel lesen
22.05.23Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes410The study achieved its objective on the primary endpoint, the reduction of fasting blood glucose, a risk factor for type 2 diabetes, at a 5g daily dose in 3 intakes per day, with a high statistical...
► Artikel lesen
03.05.23Valbiotis - Combined Annual Shareholders General Meeting held on May 2, 2023578Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic...
► Artikel lesen
26.04.23Valbiotis announces the release of the Universal Registration Document374Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and...
► Artikel lesen
14.04.23Valbiotis Announces Its Combined Shareholders General Meeting Will Be Held on May 2, 2023621Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1